The Company's non-GAAP adjusted net income for the third quarter of fiscal 2008 increased 209% to $84.9 million compared to the Company's non-GAAP adjusted net income of $27.5 million in the third quarter of fiscal 2007. The Company's fiscal 2008 third quarter non-GAAP adjusted net income excludes a $30.6 million charge to operating expenses to amortize the intangible assets acquired from Cytyc, AEG, BioLucent, Fischer, R2 and Suros and the $6.4 million restructuring charge.
Non-GAAP adjusted net income and non-GAAP adjusted EPS are non-GAAP financial measures. A reconciliation of adjusted net income and adjusted EPS to the Company's net income (loss) and EPS for the third quarter and first nine months of fiscal 2008 and 2007 is set forth in the supplemental disclosure schedule attached to this press release. When analyzing the Company's operating performance, investors should not consider these non-GAAP measures as a substitute for net income and EPS prepared in accordance with GAAP.
During the third quarter, Hologic recognized as revenue the sale of 429 Selenia full-field digital mammography systems. At June 28, 2008, the Company's backlog for orders of Selenia systems was 501 systems, including ten orders for Selenia Dimensions tomosynthesis systems for international markets, and total backlog for all products was $378 million.
"While Selenia revenue units were at a record level, revenue dollars
fell slightly short of our expectations. This was primarily related t
'/>"/>
| SOURCE Hologic, Inc. Copyright©2008 PR Newswire. All rights reserved |